7-(4-Chlorophenylsulfonamido)-1,2,3,4-Tetrahydroisoquinoline, Hydrochloride | 81885-69-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 7-(4-Chlorophenylsulfonamido)-1,2,3,4-Tetrahydroisoquinoline, Hydrochloride
• 英文别名: 4-chloro-N-(1,2,3,4-tetrahydroisoquinolin-7-yl)benzenesulfonamide;hydrochloride
• CAS: 81885-69-0
• 化学式: C₁₅H₁₅ClN₂O₂S*ClH
• 分子量: 359.276
• InChiKey: BNTHUQGMUUDNLA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.21
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  66.6
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Benzenesulfonamide derivatives
  申请人：Cooper G David

  公开号：US20050085461A1

  公开（公告）日：2005-04-21

  The invention provides compounds of formula (I) wherein A and B represent the groups CH 2 ) m — and CH 2 ) n — respectively; R 1 represents hydrogen or C 1-4 alkyl; R 2 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC 1-6 alkyl, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl, C 1-6 alkoxy, —(CH 2 ) p C 3-6 cycloalkyl, —(CH 2 ) p C 3-6 cycloalkyloxy, —COC 1-6 alkyl, —SO 2 C 1-6 alkyl, —SOC 1-6 alkyl, —S-C 1-6 alkyl, —CO 2 C 1-6 alkyl, —CO 2 NR 7 R 8 , —SO 2 NR 7 R 8 , —(CH 2 ) p NR 7 R 8 , —(CH 2 ) p NR 7 COR 8 , optionally substituted aryl, optionally substituted heteroaryl or a fused bicyclic heterocyclic ring system; R 3 represents hydrogen or C 1-6 alkyl; R 4 represents halogen, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl, C 1-6 alkoxy, —(CH 2 ) p C 3-6 cycloalkyl or —(CH 2 ) p C 3-6 cycloalkyloxy; R 5 and R 6 each independently represent hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC 1-6 alkyl, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl, C 1-6 alkoxy, —(CH 2 ) p C 3-6 cycloalkyl, —(CH 2 ) p C 3-6 cycloalkyloxy, —COC 1-6 alkyl, —SO 2 C 1-6 alkyl, —SOC 1-6 alkyl, —S—C 1-6 alkyl, —CO 2 C 1-6 alkyl, —CO 2 NR 7 R 8 , —SO 2 NR 7 R 8 , —(CH 2 ) p NR 7 R 8 , —(CH 2 ) p NR 7 COR 8 , optionally substituted aryl, optionally substituted heteroaryl or a fused bicyclic heterocyclic ring system; R 7 and R 8 each independently represent hydrogen or C 1-6 alkyl; m and n independently represent an integer selected from 1 and 2; p independently represents an integer selected from 0, 1, 2 and 3; or a pharmaceutically acceptable salt or solvate thereof, with the proviso that the compounds 4-methyl-N-(1,2,3,4-tetrahydroisoquinolin-6-yl)-benzenesulfonamide, 7-(4-chlorophenyl)sulfonamido-1,2,3,4-tetrahydroisoquinoline hydrochloride and N-(2-ethyl-5-isoindolinyl)-p-toluenesulfonamide are excluded. The compounds are useful in therapy, in particular as antipsychotic agents.

  该发明提供了式（I）的化合物，其中A和B分别代表基团CH2）m-和 ）n-; R1代表氢或C1-4烷基; R2代表氢，卤素，羟基，氰基，硝基，羟基C1-6烷基，三氟甲基，三氟甲氧基，C1-6烷基，C1-6烷氧基， -（ ）pC3-6环烷基， -（ ）pC3-6环烷氧基， -COC1-6烷基， -SO2C1-6烷基， -SOC1-6烷基， -S-C1-6烷基， -CO2C1-6烷基， -CO2NR7R8， -SO2NR7R8， -（ ）pNR7R8， -（ ）pNR7COR8，可选地取代的芳基，可选地取代的杂环芳基或融合的双环杂环环系; R3代表氢或C1-6烷基; R4代表卤素，三氟甲基，三氟甲氧基，C1-6烷基，C1-6烷氧基， -（ ）pC3-6环烷基或 -（ ）pC3-6环烷氧基; R5和R6各自独立地代表氢，卤素，羟基，氰基，硝基，羟基C1-6烷基，三氟甲基，三氟甲氧基，C1-6烷基，C1-6烷氧基， -（ ）pC3-6环烷基， -（ ）pC3-6环烷氧基， -COC1-6烷基， -SO2C1-6烷基， -SOC1-6烷基， -S-C1-6烷基， -CO2C1-6烷基， -CO2NR7R8， -SO2NR7R8， -（ ）pNR7R8， -（ ）pNR7COR8，可选地取代的芳基，可选地取代的杂环芳基或融合的双环杂环环系; R7和R8各自独立地代表氢或C1-6烷基; m和n各自独立地代表选自1和2的整数; p独立地代表选自0、1、2和3的整数; 或其药学上可接受的盐或溶剂，但不包括4-甲基-N-（1,2,3,4-四氢异喹啉-6-基）-苯磺酰胺，7-（4-氯苯基）磺酰胺-1,2,3,4-四氢异喹啉盐酸盐和N-（2-乙基-5-异吲哚基）-对甲苯磺酰胺。该化合物在治疗中有用，特别是作为抗精神病药物。
• Antiallergic imidodisulfamides
  申请人：SMITHKLINE BECKMAN CORPORATION

  公开号：EP0049135B1

  公开（公告）日：1984-04-11
• BENZENESULFONAMIDE DERIVATIVES AND THEIR USE AS DOPAMINE D3 AND D2 RECEPTOR LIGANDS
  申请人：GLAXO GROUP LIMITED

  公开号：EP1495004A2

  公开（公告）日：2005-01-12
• US4321254A
  申请人：——

  公开号：US4321254A

  公开（公告）日：1982-03-23
• [EN] BENZENESULFONAMIDE DERIVATIVES<br/>[FR] DERIVES BENZENESULFONAMIDE
  申请人：GLAXO GROUP LTD

  公开号：WO2003068732A2

  公开（公告）日：2003-08-21

  The invention provides compounds of formula (I) wherein A and B represent the groups -(CH2)m- and -(CH2)n- respectively; R1 represents hydrogen or C1-6alkyl; R2 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC1-6alkyl, trifluoromethyl, trifluoromethoxy, C1-6alkyl, C1-6alkoxy, -(CH2)pC3-6cycloalkyl, -(CH2)pC3-6cycloalkyloxy, -COC1-6alkyl, -SOC1-6alkyl, -SOC1-6alkyl, -S-C1-6alkyl, -COC1-6alkyl, -CO2NR7R8, -SO2NR7R8, -(CH2)pNR7R8, -(CH2)pNR7COR8, optionally substituted aryl, optionally substituted heteroaryl or a fused bicyclic heterocyclic ring system; R3 represents hydrogen or C1-6alkyl; R4 represents halogen, trifluoromethyl, trifluoromethoxy, C1-6alkyl, C1-6alkoxy, -(CH2)pC3-6cycloalkyl or -(CH2)pC3-6cycloalkyloxy; R5 and R6 each independently represent hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC1-6alkyl, trifluoromethyl, trifluoromethoxy, C1-6alkyl, C1-6alkoxy, -(CH2)pC3-6cycloalkyl, -(CH2)pC3-6cycloalkyloxy, -COC1-6alkyl, -SO2C1-6alkyl, -SOC1-6alkyl, -S-C1-6alkyl, -CO2C1-6alkyl, -CO2NR7R8, -SO2NR7R8, -(CH2)pNR7R8, -(CH2)pNR7COR8, optionally substituted aryl, optionally substituted heteroaryl or a fused bicyclic heterocyclic ring system; R7 and R8 each independently represent hydrogen or C1-6alkyl;m and n independently represent an integer selected from 1 and 2;p independently represents an integer selected from 0, 1, 2 and 3; or a pharmaceutically acceptable salt or solvate thereof,with the proviso that the compounds 4-methyl-N-(1,2,3,4-tetrahydroisoquinolin-6-yl)-benzenesulfonamide, 7-(4-chlorophenyl)sulfonamido-1,2,3,4-tetrahydroisoquinoline hydrochloride and N-(2-ethyl-5-isoindolinyl)-p-toluenesulfonamide are excluded.The compounds are useful in therapy, in particular as antipsychotic agents.